<DOC>
	<DOCNO>NCT01059435</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability AMG 785 follow single dose subcutaneous ( SC ) intravenous ( IV ) administration healthy men postmenopausal woman .</brief_summary>
	<brief_title>A First-in-human Study Evaluating AMG 785 Healthy Men Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>Healthy male female 45 59 year age , inclusive Postmenopausal female define 12 continuous month spontaneous amenorrhea confirm serum folliclestimulating hormone ( FSH ) result &gt; 40mIU/mL , 6 week postsurgical bilateral oophorectomy ( without hysterectomy ) Males must agree use condom sexual intercourse female partner reproductive potential female partner use additional effective mean contraception abstain sexual intercourse duration study Has history evidence clinically significant disorder , condition disease would pose risk subject safety interfere study evaluation , procedures completion Diagnosed condition affect bone metabolism Administration follow medication within 6 month study drug administration : Hormone replacement therapy [ Infrequent use estrogen vaginal cream ( &lt; 3 time per week ) allow . ] Calcitonin Parathyroid hormone ( derivative ) Supplemental Vitamin D &gt; 1,000 IU/day Glucocorticosteroids ( inhaled topical corticosteroid administer 2 week enrollment date allow ) Anabolic steroid Calcitriol , available analogue Administration follow medication within 12 month study drug administration : Bisphosphonates Fluoride osteoporosis Administration herbal medication within 2 week 5 halflives ( whichever longer ) study drug administration Greatly differ level physical activity constant level intense physical exercise 6 month study drug administration Routine alcohol intake &gt; 2 drink per day , average , within 6 month study drug administration Known sensitivity mammalianderived drug preparation Known hepatitis B surface antigen , hepatitis C virus , human immunodeficiency virus ( HIV ) positive , know diagnosis acquire immunodeficiency syndrome ( AIDS ) Any organic psychiatric disorder may pose risk subject safety may prevent subject complete study interfere interpretation study result Unavailable followup assessment concern subject 's compliance protocol procedures Any condition might reduce chance obtain data require protocol might compromise ability give truly informed consent Has history drug alcohol abuse last 12 month and/or positive urine test result screen admission Has clinically significant abnormality screen physical examination , electrocardiogram ( ECG ) , laboratory evaluation Has participate another clinical study within 4 week screen within 5 time halflife investigational agent clinical study , know Weight ≥ 98 kilogram ( 216 pound ) and/or height ≥ 78 inch Has donate lose 400 milliliter blood plasma within 8 week study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Amgen</keyword>
	<keyword>First Human</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Phase 1</keyword>
</DOC>